

ACCORD's Mortality Risk Persisted to 5 Years

BY SHARON WORCESTER

FROM THE NEW ENGLAND
JOURNAL OF MEDICINE

Outcomes out to 5 years in the ACCORD trial are consistent with those that brought the study to a halt after a mean of 3.7 years of intensive glucose-lowering therapy reduced the risk of nonfatal myocardial infarction in patients with advanced type 2 diabetes

and a high risk of cardiovascular disease, but increased the risk of death.

Thus, a therapeutic approach that targets glycated hemoglobin levels below 6% cannot be recommended in this population, Dr. Hertzl C. Gerstein of McMaster University, Hamilton, Ont., and colleagues from the Action to Control Cardiovascular Risk in Diabetes Study Group reported.

ACCORD participants were 10,108

type 2 diabetes patients with cardiovascular disease who were randomly assigned to receive intensive glucose-lowering therapy to a target hemoglobin A_{1c} below 6.0% or to standard therapy with a target HbA_{1c} of 7.0%-7.9%. The intensive therapy was terminated after a mean of 3.5 years because of higher mortality in the intensive treatment group, and patients from that group began receiving standard therapy. The cur-

rent findings reflect an additional 0.2 months of intensive therapy not previously reported, and up to 17 months of additional follow-up.

Prior to the transition, the incidence of the primary outcome (a composite of nonfatal MI, nonfatal stroke, or death from cardiovascular causes) was 2.0% per year in the intensive therapy group, and 2.2% per year in the standard therapy group (hazard ratio 0.90).

Although the intensive therapy did lower the rate of nonfatal MI (1.08% vs. 1.35%, HR 0.79), it was also associated with a nonsignificant increased rate of death from cardiovascular causes (0.71% vs. 0.55%, HR 1.27).

"These divergent effects were retained at the end of the study, with a rate of nonfatal MI in the intensive-therapy groups that was lower than in the standard-therapy group (1.18 vs. 1.42; hazard ratio 0.82) ... and a rate of death from cardiovascular causes that was higher

important adverse renal effects were observed in clinical studies. Assessments included creatinine clearance; measurements of blood urea nitrogen (BUN), creatinine, and electrolytes in serum; urine specific gravity and pH; and examination of urine sediment. **Studies in Men and Women with Glucocorticoid-Induced Osteoporosis** The safety of FORTEO in the treatment of men and women with glucocorticoid-induced osteoporosis was assessed in a randomized, double-blind, active-controlled trial of 428 patients (19% men, 81% women) aged 22 to 89 years (mean 57 years) treated with \geq 5mg per day prednisone or equivalent for a minimum of 3 months. The duration of the trial was 18 months with 214 patients exposed to FORTEO and 214 patients exposed to oral daily bisphosphonate (active control). All patients received 1000 mg of calcium plus 800 IU of vitamin D supplementation per day. The incidence of all cause mortality was 4% in the FORTEO group and 6% in the active control group. The incidence of serious adverse events was 21% in FORTEO patients and 18% in active control patients, and included pneumonia (3% FORTEO, 1% active control). Early discontinuation because of adverse events occurred in 15% of FORTEO patients and 12% of active control patients, and included dizziness (2% FORTEO, 0% active control). Adverse events reported at a higher incidence in the FORTEO group and with at least a 2% difference in FORTEO-treated patients compared with active control-treated patients were: nausea (14%, 7%), gastritis (7%, 3%), pneumonia (6%, 3%), dyspnea (6%, 3%), insomnia (5%, 1%), anxiety (4%, 1%), and herpes zoster (3%, 1%), respectively. **Postmarketing Experience:** The following adverse reactions have been identified during postapproval use of FORTEO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. **Osteosarcoma:** Cases of bone tumor and osteosarcoma have been reported rarely in the postmarketing period. The causality to FORTEO use is unclear. Long term osteosarcoma surveillance studies are ongoing. **Hypercalcemia:** Hypercalcemia greater than 13.0 mg/dL has been reported with FORTEO use. Adverse events reported since market introduction that were temporally (but not necessarily causally) related to FORTEO therapy include the following: **Allergic Reactions:** Anaphylactic reactions, drug hypersensitivity, angioedema, urticaria; **Investigations:** Hyperuricemia; **Respiratory System:** Acute dyspnea, chest pain; **Musculoskeletal:** Muscle spasms of the leg or back; **Other:** Injection site reactions including injection site pain, swelling and bruising; oro-facial edema.

USE IN SPECIFIC POPULATIONS

Pregnancy Category C. There are no adequate and well-controlled studies of FORTEO in pregnant women. In animal studies, teriparatide increased skeletal deviations and variations in mouse offspring at doses more than 60 times the equivalent human dose and produced mild growth retardation and reduced motor activity in rat offspring at doses more than 120 times the equivalent human dose. FORTEO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In animal studies, pregnant mice received teriparatide during organogenesis at subcutaneous doses 8 to 267 times the human dose. At doses \geq 60 times the human dose, the fetuses showed an increased incidence of skeletal deviations or variations (interrupted rib, extra vertebra or rib). When pregnant rats received subcutaneous teriparatide during organogenesis at doses 16 to 540 times the human dose, the fetuses showed no abnormal findings. In a perinatal/postnatal study, pregnant rats received subcutaneous teriparatide from organogenesis through lactation. Mild growth retardation in female offspring at doses \geq 120 times the human dose (based on surface area, mcg/m²). Mild growth retardation in male offspring and reduced motor activity in both male and female offspring occurred at maternal doses 540 times the human dose. There were no developmental or reproductive effects in mice or rats at doses 8 or 16 times the human dose, respectively. Exposure multiples were normalized based on body surface area (mcg/m²). Actual animal doses: mice (30 to 1000 mcg/kg/day); rats (30 to 1000 mcg/kg/day). **Nursing Mothers:** It is not known whether teriparatide is excreted

in human milk. Because of the potential for tumorigenicity shown for teriparatide in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Pediatric Use:** The safety and efficacy of FORTEO have not been established in any pediatric population. FORTEO should not be prescribed in patients at an increased baseline risk of osteosarcoma which include pediatric and young adult patients with open epiphyses. Therefore, FORTEO is not indicated for use in pediatric or young adult patients with open epiphyses. **Geriatric Use:** Of the patients receiving FORTEO in the osteoporosis trial of 1637 postmenopausal women, 75% were 65 years of age and over and 23% were 75 years of age and over. Of the patients receiving FORTEO in the osteoporosis trial of 437 men, 39% were 65 years of age and over and 13% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. **Hepatic Impairment:** No studies have been performed in patients with hepatic impairment. **Renal Impairment:** In 5 patients with severe renal impairment (CrCl $<$ 30 mL/min), the AUC and T_{1/2} of teriparatide were increased by 73% and 77%, respectively. Maximum serum concentration of teriparatide was not increased.

OVERDOSAGE

Incidents of overdose in humans have not been reported in clinical trials. Teriparatide has been administered in single doses of up to 100 mcg and in repeated doses of up to 60 mcg/day for 6 weeks. The effects of overdose that might be expected include a delayed hypercalcemic effect and risk of orthostatic hypotension. Nausea, vomiting, dizziness, and headache might also occur. In postmarketing spontaneous reports, there have been cases of medication errors in which the entire contents (up to 800 mcg) of the FORTEO delivery device (pen) have been administered as a single dose. Transient events reported have included nausea, weakness/lethargy and hypotension. In some cases, no adverse events occurred as a result of the overdose. No fatalities associated with overdose have been reported. **Overdose Management** There is no specific antidote for teriparatide. Treatment of suspected overdose should include discontinuation of FORTEO, monitoring of serum calcium and phosphorus, and implementation of appropriate supportive measures, such as hydration.

DOSAGE FORMS AND STRENGTHS

Multi-dose prefilled delivery device (pen) for subcutaneous injection containing 28 daily doses of 20 mcg.

PATIENT COUNSELING INFORMATION

Patients should read the FDA-approved *Medication Guide* and delivery device (pen) *User Manual* before starting therapy with FORTEO and re-read them each time the prescription is renewed. Patients need to understand and follow the instructions in the FORTEO delivery device *User Manual*. Failure to do so may result in inaccurate dosing.

12/13/2010

PLEASE SEE FULL PRESCRIBING INFORMATION FOR ADDITIONAL INFORMATION.

Literature revised December 13, 2010

Manufactured by Lilly France – F-67640 Fegersheim, France
for Eli Lilly and Company – Indianapolis, IN 46285, USA
www.forteo.com

Copyright © 2002, 2009, 2010 Eli Lilly and Company. All rights reserved.
PA 097 FSAM00

Rx only.

PA 097 FSAM00

FORTEO® (teriparatide [rDNA origin] 20 mcg for injection)

PA 097 FSAM00

FORTEO® (teriparatide [rDNA origin] 20 mcg for injection)

PA 097 FSAM00



HbA_{1c} levels below 6% should be avoided, said Dr. Hertzl C. Gerstein.

(0.74 vs. 0.57; hazard ratio 1.29)," they found (N. Engl. J. Med. 2011;364:818-28).

At the time of transition, the death rate from any cause was a significant 21% higher in the intensive therapy group (1.42 vs. 1.16), and it remained higher – by 19% – at the end of the study (1.53 vs. 1.27).

The findings indicate that 3.7 years of intensive therapy to target normal HbA_{1c} in a high-risk population does not significantly lower the number of major cardiovascular events after 5 years, compared with therapy that targets "levels that are more typically achieved in person in the United States and Canada (i.e., 7-7.9%)," and indeed, the intensive approach was associated with more deaths, they said.

ACCORD was supported by the National Institutes of Health and the Centers for Disease Control and Prevention. Study medication, equipment, or supplies were provided by numerous pharmaceutical companies. Dr. Gerstein has received consulting fees, institutional grant support, and/or lecture fees from Sanofi-Aventis, GlaxoSmithKline, Novo Nordisk, and several other drug companies. Individual ACCORD Study Group members' disclosures are available with the full text of the article at www.nejm.com. ■